Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…

I don’t think it’s any secret that I have a thing for heroes, super-powered or otherwise. Just look at the artwork for this column!…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…